Search Results

You are looking at 1 - 8 of 8 items for :

  • pharmacokinetics x
  • History and Ethics of Medicine x
Clear All
Open access

Vanja Dzambazovska-Trajkovska, Jordan Nojkov, Andrijan Kartalov, Biljana Kuzmanovska, Tatjana Spiroska, Redzep Seljmani, Gjorgji Trajkovski, Nadica Matevska-Geshkovska and Aleksandar Dimovski

brain opioid receptor availability in central and peripheral neuropathic pain. Pain. 2007 Jan; 127(1–2): 183–94. 5. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006; 234: 4–33. 51. 6. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112: 457–473. 52. 7. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang’s J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1

Open access

Goce Spasovski

nonadherence. Am J Transplant. 2012; 12(2): 388-99. 22. Vítko S, Ferkl M. Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. Kidney Int Suppl. 2010; (115): S12-6. 23. Alloway RR, Sadaka B, Trofe-Clark J, et al. A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients. Am J Transplant. 2012; 12(10): 2825-2831. 24. Melilli E

Open access

Ana Filipce, Zorica Naumovska, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Katerina Brezovska, Jasmina Tonic-Ribarska, Aleksandra Grozdanova, Ljubica Suturkova and Marija Raleva

, Bravaccio C, Radice S, Capuano A. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J. 2018 May 22; 18(3): 422–430. 4. Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, Eap CB. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clin Pharmacokinet. 2015 Dec; 54(12): 1259–72. 5. Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone

Open access

Dragica Zendelovska, Kristina Pavlovska, Emilija Atanasovska, Kalina Gjorgjievska and Marija Petrusevska

REFERENCES 1. Shorvon S, Perucca E, Engel J., Jr. The treatment of epilepsy. 3. UK: Wiley-Blackwell West Sussex; 2009. 2. Sruthi A, Tejaswi P, Thanuja N, Sudheer Kumar D, Vivek Sagar V. Simple RP-HPLC method for estimation of diazepam in tablet dosage form. J Pharm Res 2013; 6(1):140-144 3. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA. Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm. 1977; (5

Open access

Zorica Naumovska, Aleksandra K. Nestorovska, Zoran Sterjev, Ana Filipce, Aleksandar Dimovski and Ljubica Suturkova

Res. 2008; 58: 344-347. 12. Uhr M, Grauer MT, Yassouridis A and Ebinger M. Blood- brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res. 2007; 41: 179-188. 13. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, et al. CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008; 30: 474-482. 14. Loscher W and Potschka H. Role of multidrug transporters in pharmacoresistance to

Open access

H. K. Aggarwal, Deepak Jain, Pulkit Chhabra and R. K. Yadav

from kidney disease: improving global outcomes (KDIGO). Kidney Int 2006; 69: 1945-53. 4. Ersoy FF, Passadakis SP, Tam P, Mammos ED, Katopodis PK, Ozener C et al. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 2006; 24(1): 79-86. 5. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18(2) : 75-85. 6. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest 1996; 97: 2692-6. 7. Liberman UA, Weiss SR, Broll J

Open access

Zorica Naumovska, Aleksandra K. Nesterovska, Ana Filipce, Zoran Sterjev, Katerina Brezovska, Aleksandar Dimovski and Ljubica Suturkova

. Nikisch G, Eap CB and Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res. 2008; 58: 344-347. 43. Uhr M, Grauer MT, Yassouridis A and Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res. 2007; 41: 179-188. 44. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, et al. CYP2D6 and ABCB1 genetic

Open access

Zorica Naumovska, Aleksandra K. Nestorovska, Zoran Sterjev, Ana Filipce, Aleksandra Grozdanova, Aleksandar Dimovski, Ljubica Suturkova and Vladimir Serafimoski

. Risperidone and Paliperidone Inhibit P-Glycoprotein Activity In Vitro Neuropsychopharmacology. 2007; 32: 757–764. 31. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12: 437–450. 32. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters inthe pharmacokinetics of drugs. Pharmacol Ther. 2006 Nov;112(2):457-73. Review. 33. Kimchi-Sarfaty C, Marple AH, Shinar S